OMZYTA Powder and solvent for suspension for injection Ref.[115608] Active ingredients: Measles, live attenuated Mumps, live attenuated Rubella, live attenuated

Source: Health Products Regulatory Authority (ZA)  Revision Year: 2020  Publisher: MSD (Pty) Ltd, 117 16 th Road, Halfway House, 1685, South Africa

Product name and form

OMZYTA Powder and Solvent for Suspension for Injection

(Measles, Mumps and Rubella Virus Vaccine Live)

Pharmaceutical Form

Powder:

Before reconstitution, the lyophilised vaccine is a light yellow compact crystalline plug.

Reconstituted solution:

OMZYTA, when reconstituted, is a clear yellow solution.

Diluent:

Clear, colourless liquid.

Qualitative and quantitative composition

When reconstituted as directed, the dose for injection is 0,5 mL and contains not less than 1 000 CCID50 (50% cell culture infectious dose) of measles virus, 12 500 CCID50 of mumps virus and 1 000 CCID50 of rubella virus.

Active Ingredient

Rubella virus vaccine contains live attenuated rubella virus, produced in human diploid (MRC-5) cells. It is a virus vaccine for active immunization against rubella that is subcutaneously administered.

List of Excipients

Sorbitol, sodium phosphate, sucrose, hydrolysed gelatin, recombinant human albumin, foetal bovine serum, other buffer and media ingredients and approximately 25 µg of neomycin.

The product contains no preservative.

Diluent: Water for injection.

Pack sizes and marketing

Vial Powder: 3 mL clear Type 1 borosilicate glass vial with a grey stopper (butyl rubber) and a blue plastic cap.

Sterile Diluent Vial: 0,7 mL water for injection in a 3 mL glass vial with grey rubber stopper and dark grey plastic flipoff cap.

Carton: 3 mL vial of OMZYTA and 3 mL vial of DILUENT are packed together in a cardboard carton with the package insert and patient information leaflet.

Pack sizes of 1 or 10 vials.

Not all pack sizes may be marketed.

Marketing authorization holder

MSD (Pty) Ltd, 117 16th Road, Halfway House, 1685, South Africa

Marketing authorization dates and numbers

50/30.2/0576

29 September 2017

Drugs

Drug Countries
OMZYTA South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.